<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3-5752-23
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2009
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        COMBIGAN
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TIMOLOL MALEATE,BRIMONIDINE TARTRATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5,2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ophthalmic use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Dropper Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        21
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        31.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ALLERGAN PHARMACEUTICALS LTD" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ALLERGAN PHARMACEUTICALS LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ABBVIE LIMITED
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01EA05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        S01ED01
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>COMBIGAN is an eye drop that is used to control glaucoma. It contains two different medicines (brimonidine and timolol) that both reduce high pressure in the eye. Brimonidine belongs to a group of medicines called alpha-2 adrenergic receptor agonists. Timolol belongs to a group of medicines called beta-blockers. COMBIGAN is prescribed to reduce high pressure in the eye when beta-blocker eye drops used alone are not enough.</p><p>&nbsp;</p><p>Your eye contains a clear, watery liquid that feeds the inside of the eye. Liquid is constantly being drained out of the eye and new liquid is made to replace this. If the liquid cannot drain out quickly enough, the pressure inside the eye builds up and could eventually damage your sight. COMBIGAN works by reducing the production of liquid and increasing the amount of liquid that is drained. This reduces the pressure inside the eye whilst still continuing to feed the eye.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p><strong>Do not use COMBIGAN </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic</strong> (hypersensitive) to <strong>brimonidine tartrate, timolol, beta-blockers </strong>or any of the <strong>other ingredients of</strong> this medicine (listed in section 6).<strong> </strong>Symptoms of an allergic reaction may include swelling of the face, lips and throat, wheeziness, feeling faint, shortness of breath, itching or redness around the eye.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have now or have had in the past respiratory problems such as <strong>asthma,</strong> <strong>severe chronic obstructive</strong> <strong>bronchitis </strong>(severe lung disease which may cause wheeziness, difficulty in breathing and/or long standing cough).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have heart problems such as<strong> low heart rate, heart failure,</strong> <strong>heart beat disorders</strong> (unless controlled by a pacemaker).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking <strong>monoamine oxidase (MAO) inhibitors</strong> or certain other <strong>antidepressant drugs.</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;If you think any of these points apply to you, do not use COMBIGAN until you have talked again to your doctor.</p><p>&nbsp;</p><p><strong>&nbsp;Warnings and precautions</strong></p><p>&nbsp;Talk to your doctor before using COMBIGAN</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have now or have had in the past</p><p>&nbsp;</p><p>-&nbsp;&nbsp; coronary heart disease (symptoms can include chest pain or tightness, breathlessness or choking), heart failure, low blood pressure</p><p>-&nbsp;&nbsp; disturbances of heart rate such as slow heart beat</p><p>-&nbsp;&nbsp; breathing problems, asthma or chronic obstructive pulmonary disease</p><p>-&nbsp;&nbsp; poor blood circulation disease (such as Raynaud&rsquo;s disease or Raynaud&rsquo;s syndrome)</p><p>-&nbsp;&nbsp; diabetes as timolol may mask signs and symptoms of low blood sugar levels</p><p>-&nbsp;&nbsp; overactivity of the thyroid gland as timolol may mask signs and symptoms</p><p>-&nbsp;&nbsp; kidney or liver problems</p><p>-&nbsp;&nbsp; tumour of the adrenal gland</p><p>-&nbsp;&nbsp; eye surgery to lower the pressure in your eye</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer or have suffered from any allergy (e.g. hayfever, eczema) or a severe allergic reaction be aware that the usual dose of adrenaline used to control a severe reaction may need to be increased.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell the doctor before you have an operation that you are using COMBIGAN, as the timolol may change effects of some medicines during anaesthesia.</p><p>&nbsp;</p><p>Children and adolescents&nbsp;</p><p>COMBIGAN should not be used in children less than 2 years old and should not usually be used in children aged 2 to 17.</p><p>&nbsp;</p><p><strong>Other medicines and COMBIGAN</strong></p><p><strong>&nbsp;</strong></p><p><strong>COMBIGAN can affect or be affected by other medicines you are using, including other eye drops for the treatment of glaucoma.</strong> Tell your doctor or pharmacist if you are taking, have recently taken or might take other medicines, including medicines for any condition, even if unrelated to your eye condition, including medicines obtained without a prescription.</p><p>There are a number of medicines which may interfere with COMBIGAN, so it is particularly important to tell your doctor if you are taking:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain killers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to help you sleep or for anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat high blood pressure (hypertension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for heart conditions (for example an abnormal heartbeat) such as beta blockers, digoxin or quinidine (used to treat heart conditions and some types of malaria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat diabetes or high blood sugar</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for depression such as fluoxetine and paroxetine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; another eye drop used to lower high pressure in the eye (glaucoma)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat severe allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that affect some of the hormones in your body, like adrenaline and dopamine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that affect the muscles in your blood vessels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat heartburn or stomach ulcers</p><p>&nbsp;</p><p>If the dose of any of your current medicines is changed or if you are regularly consuming alcohol you should tell your doctor.</p><p>If you are due to have an anaesthetic, you should tell the doctor or dentist that you are taking COMBIGAN.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine</p><p>&nbsp;</p><p>Do not use COMBIGAN if you are pregnant unless your doctor considers it necessary.</p><p>&nbsp;</p><p>Do not use COMBIGAN if you are breast-feeding.&nbsp; Timolol may get into your milk.&nbsp; Ask your doctor for advice before taking any medicine during breast-feeding.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>COMBIGAN may cause drowsiness, tiredness or blurred vision in some &nbsp;patients. Do not drive or use any tools or machines until the symptoms have cleared. If you experience any problems, talk to your doctor.</p><p>&nbsp;COMBIGAN contains benzalkonium chloride</p><p>&nbsp;</p><p>This medicine contains 0.25 mg benzalkonium chloride in each 5 ml of solution which is equivalent to 0.05 mg/ml.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. You should remove contact lenses before using this medicine and put them back 15 minutes afterwards.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Benzalkonium chloride may also cause eye irritation, especially if you have dry eyes or disorders of the cornea (the clear layer at the front of the eye). If you feel abnormal eye sensation, stinging or pain in the eye after using this medicine, talk to your doctor</p><p>&nbsp;</p><p><strong>COMBIGAN contains phosphates:</strong></p><p>&nbsp;</p><p>This medicine contains 52.9 mg phosphates in each 5 ml of solution which is equivalent to 10.58 mg/ml.</p><p>&nbsp;</p><p>If you suffer from severe damage to the clear layer at the front of the eye (the cornea), phosphates may cause in very rare cases cloudy patches on the cornea due to calcium build-up during treatment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. COMBIGAN must not be used in infants below 2 years of age.&nbsp; COMBIGAN should not usually be used in children and adolescents (from 2 to 17 years).</p><p>&nbsp;</p><p>The recommended dose is one drop of COMBIGAN, twice a day about 12 hours apart. Do not change the dose or stop taking it without speaking to your doctor.</p><p>&nbsp;</p><p>If you have other eye drops as well as COMBIGAN, <strong>leave at least 5 minutes</strong> between using COMBIGAN and the other eye drops.</p><p>&nbsp;</p><p><strong>Instructions for use</strong></p><p>You must not use the bottle if the tamper-proof seal on the bottle neck is broken before you first begin to use it.</p><p>&nbsp;</p><p>Wash your hands before opening the bottle. Tilt your head back and look at the ceiling.</p><p>&nbsp;</p><p>&nbsp;</p><p><img alt="" width="620" height="173" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently pull down the lower eyelid until there is a small pocket.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turn the bottle upside down and squeeze it to release one drop into each eye that needs treatment.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Let go of the lower lid, and close your eye.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the eye closed and press your finger against the corner of your eye (the side where your eye meets your nose) for two minutes.&nbsp; This helps stop COMBIGAN getting into the rest of the body.</p><p>&nbsp;</p><p>If a drop misses your eye, try again.</p><p>&nbsp;</p><p>To avoid contamination, do not let the tip of the bottle touch your eye or anything else. Put the screw-cap back on to close the bottle, straight after you have used it.</p><p>&nbsp;</p><p><strong>If you use more COMBIGAN than you should</strong></p><p><em>Adults</em></p><p>If you use more COMBIGAN than you should, it is unlikely to cause you any harm. Put your next drop in at the usual time. If you are worried, talk to your doctor or pharmacist.</p><p>&nbsp;</p><p><em>Babies and Children</em></p><p>Several cases of overdose have been reported in babies and children receiving brimonidine (one of the ingredients of COMBIGAN) as part of medical treatment for glaucoma. Signs include sleepiness, floppiness, low body temperature, paleness and breathing difficulties. Should this happen, contact your doctor immediately.</p><p>&nbsp;</p><p><em>Adults and Children</em></p><p>If COMBIGAN has been accidentally swallowed then you should contact your doctor immediately.</p><p>&nbsp;</p><p><strong>If you forget to use COMBIGAN</strong></p><p>If you forget to use COMBIGAN, use a single drop in each eye that needs treatment as soon as you remember, and then go back to your regular routine. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop using COMBIGAN</strong></p><p>COMBIGAN should be used every day to work properly.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If you experience any of the following side effects, please contact your doctor immediately:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart failure (e.g. chest pain) or irregular heart rate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased or decreased heart rate or low blood pressure</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Affecting the eye</u></em></p><p><em>&nbsp;</em></p><p><em>Very common&nbsp;&nbsp;&nbsp; (may affect more than 1 in 10 people):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye redness or burning</p><p>&nbsp;</p><p><em>Common (may affect up to 1 in 10 people)</em>:<em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stinging or pain in the eye</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction in the eye or on the skin around the eye</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Small breaks in the surface of the eye (with or without inflammation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling, redness or inflammation of the eyelid</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritation, or a feeling of something in the eye</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching of the eye and eyelid</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Follicles or white spots on the see-through layer which covers the surface of the eye</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vision disturbance</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tearing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye dryness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sticky eyes</p><p>&nbsp;</p><p><em>Uncommon (may affect up to 1 in 100 people):</em>&nbsp;&nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in seeing clearly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling or inflammation of the see-through layer which covers the surface of the eye</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tired eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensitivity to light</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eyelid pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Whitening of the see-through layer which covers the surface of the eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling or areas of inflammation under the surface of the eye</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Floaters in front of the eyes</p><p>&nbsp;</p><p><em>Not known (frequency cannot be estimated from the available data):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision</p><p>&nbsp;</p><p><em><u>Affecting the body</u></em></p><p>&nbsp;</p><p><em>Common (may affect up to 1 in 10 people):</em></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleepiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; General weakness</p><p>&nbsp;</p><p><em>Uncommon (may affect up to 1 in 100 people):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Light-headedness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry nose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taste disturbances</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&nbsp;</p><p><em>Not known (frequency cannot be estimated from the available data):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased or decreased heart rate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Face redness</p><p>&nbsp;</p><p>Some of these effects may be due to an allergy to any of the ingredients.&nbsp; Additional side effects have been seen with brimonidine or timolol and therefore may potentially occur with COMBIGAN.</p><p>&nbsp;</p><p>The following additional side effects have been seen with brimonidine:</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Inflammation within eye, small pupils, difficulty sleeping, cold-like symptoms, shortness of breath, symptoms involving the stomach and digestion, general allergic reactions, skin reactions including redness, face swelling, itching rash and widening of blood vessels.</p><p>&nbsp;</p><p>Like other medicines applied into eyes, COMBIGAN (brimonidine/timolol) is absorbed into the blood. Absorption of timolol, a beta blocker component of COMGIBAN, may cause similar side effects as seen with &ldquo;intravenous&rdquo; and /or &ldquo;oral&rdquo; beta-blocking agents. Incidence of side effects after topical ophthalmic administration is lower than when medicines are for example, taken by mouth or injected. Listed side effects include reactions seen within the class of beta-blockers when used for treating eye conditions:</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Generalised allergic reactions, including swelling beneath the skin (that can occur in areas such as the face and limbs, and can obstruct the airway which may cause difficulty swallowing or breathing), hives (or itchy rash), localised and generalised rash, itchiness, severe sudden life threatening allergic reaction</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Low-blood glucose levels</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Difficulty in sleeping (insomnia), nightmares, memory loss, hallucination .</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Stroke, reduced blood supply to the brain, increased signs and symptoms of myasthenia gravis (muscle disorder), unusual sensations (like pins and needles)</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Inflammation in the cornea, detachment of the layer below the retina that contains blood vessels following filtration surgery which may cause visual disturbances, decreased corneal sensitivity, corneal erosion (damage to the front layer of the eyeball), drooping of the upper eyelid (making the eye half closed), double vision</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Chest pain, oedema (fluid build up), changes in the rhythm or speed of the heartbeat, a type of heart rhythm disorder, heart attack, heart failure</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Raynaud&rsquo;s phenomenon, cold hands and feet</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Constriction of the airways in the lung (predominantly in patients with pre-existing disease) difficulty breathing, cough</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Indigestion, abdominal pain, vomiting</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Hair loss, skin rash with white silvery coloured appearance (psoriasiform rash) or worsening of psoriasis, skin rash</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Muscle pain not caused by exercise</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Sexual dysfunction, decreased libido</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Muscle weakness/tiredness</p><p>&nbsp;</p><p>Other side effects reported with eye drops containing phosphates:</p><p>Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged cornea.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>&nbsp;</p><p>If you get any of the side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in 6.</p><p>By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not Store above 25&deg;C.</p><p>Do not refrigerate or freeze.</p><p>&nbsp;</p><p>&nbsp;</p><p>Keep the bottle in the outer carton to protect it from light.</p><p>Discard four weeks after first opening.</p><p>&nbsp;</p><p>You should only use one bottle at a time.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label of the bottle and the carton after EXP:. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>You must throw away the bottle four weeks after you first opened it, even if there are still some drops left. This will help to prevent infections. To help you remember, write down the date that you opened it in the space on the carton.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What COMBIGAN contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are brimonidine tartrate and timolol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One millilitre of solution contains 2 milligrams of brimonidine tartrate and timolol maleate equivalent to 5 milligrams of timolol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are benzalkonium chloride (a preservative), sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate and purified water. Small amounts of hydrochloric acid or sodium hydroxide may be added to bring the solution to the correct pH (a measure of the acidity or alkalinity of the solution).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                COMBIGAN is a clear, greenish-yellow eye drop solution in a plastic bottle with a screw-cap. Each bottle is about half full and contains 5 ml of solution. Packs are available containing either 1 or 3 bottles. Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer</strong></p><p>Allergan Pharmaceuticals Ireland, Castlebar Road, Westport, Co Mayo, Ireland</p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder</strong></p><p>AbbVie Limited</p><p>Citywest Business Campus</p><p>Dublin 24</p><p>Ireland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in   12/ 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">كومبيجان هو قطرة للعين تُستخدم للسيطرة على الجلوكوما. وهو يحتوي على دوائين مختلفين &nbsp;(بريمونيدين و تيمولول) وكلاهما يخفض الضغط المرتفع داخل العين. ينتمي بريمونيدين إلى مجموعة من الأدوية تُسمى مشددات مستقبلات ألفا- 2 الأدرينالية. وينتمي تيمولول إلى مجموعة من الأدوية تُسمى حاصرات البيتا. يوصى بإعطاء كومبيجان لخفض الضغط المرتفع داخل العين، عندما تكون قطرات العين المحتوية على حاصرات البيتا غير كافية.</p><p dir="RTL">تحتوي العين على سائل مائي رائق يغذي العين من الداخل. هذا السائل يتم صرفه من العين بصفة مستمرة ويتم استبداله بسائل جديد. إذا لم تتم عملية صرف السائل بالسرعة الكافية، فإن الضغط داخل العين يرتفع وقد يؤدي في النهاية إلى تلف الإبصار. يعمل كومبيجان على تقليل إنتاج السائل وزيادة صرفه. هذا يقلل الضغط داخل العين مع الاستمرار في تغذية العين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا</strong><strong> تستعمل</strong><strong> كومبيجان</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك <strong>حساسية</strong> مفرطة تجاه <strong>بريمونيدين ترتارات، تيمولول، حاصرات البيتا</strong> أو &nbsp;أي من <strong>مكونات هذا الدواء لأخرى (مذكوره فى الجزء6</strong><strong>(ال</strong>. قد تضم أعراض التفاعل الأرجي (الحساسية) تورم الوجه، والشفاه والحلق، الأزيز التنفسي، الشعور بالإغماء، ضيق التنفس، الحكة أو تورد المنطقة المحيطة بالعين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك الآن أو فيما سبق مشاكل تنفسية &nbsp;مثل <strong>الربو،</strong><strong> أو</strong><strong> التهاب قصبي (شعبي) انسدادي</strong><strong> مزمن</strong><strong> شديد</strong> (مرض رئوي شديد قد يُسبب الأزيز التنفسي، صعوبة التنفس و/أو السعال طويل البقاء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل في القلب <strong>مثل</strong><strong> &nbsp;انخفاض معدل ضربات القلب، فشل قلبي، اضطرابات</strong><strong> في</strong><strong> ضربات</strong><strong> القلب</strong> (ما لم تكن تحت السيطرة بواسطة ناظمة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستعمل <strong>مثبطات</strong><strong> أحادي</strong><strong> أمين</strong><strong> أوكسيديز </strong>أو أنواع معينة أخرى من <strong>الأدوية</strong><strong> المضادة</strong><strong> للاكتئاب.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ظننت أن أي من هذه النقاط ينطبق عليك، لا تستعمل كومبيجان إلا بعد أن تتحدث مرة أخرى مع طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;تحذيرات واحتياطيات</strong></p><p dir="RTL">تحدث الى طبيبك قبل استعمال كومبيجان:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك الآن أو حدث لديك في الماضي</p><p dir="RTL">- أمراض قلب تاجية (يمكن أن تضم أعراضها ألم الصدر، أو تضيق الصدر، اللهاث أو الاختناق)، فشل قلبي، انخفاض ضغط الدم.</p><p dir="RTL">- اضطرابات معدل ضربات القلب، على سبيل المثال، بطء ضربات القلب.</p><p dir="RTL">- مشاكل تنفسية، ربو أو مرض رئوي انسدادي مزمن.</p><p dir="RTL">- أمراض سوء دوران الدم (كداء رينود أو متلازمة رينود).</p><p dir="RTL">- داء السكري لأن تيمولول من شأنه إخفاء علامات وأعراض انخفاض مستويات سكر الدم.</p><p dir="RTL">- فرط نشاط الغدة الدرقية لأن تيمولول من شأنه إخفاء العلامات والأعراض.</p><p dir="RTL">- مشاكل في الكلى أو الكبد.</p><p dir="RTL">- ورم بالغدة الكظرية.</p><p dir="RTL">- جراحة في العين لخفض الضغط داخل العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو عانيت من قبل من أي حساسية (مثل حمى القش، الإكزيما (أو أي تفاعل حساسية شديد، يجب أن تعرف أن الجرعة المعتادة من الأدرينالين التي تُستخدم للسيطرة على التفاعل الشديد قد تحتاج أن تُزاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اخبر الطبيب قبل أن تخضع لجراحة بأنك تستعمل كومبيجان، لأن من شأن تيمولول تغيير مفعول بعض الأدوية أثناء التخدير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاطفال و المراهقين </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp; ينبغي ألا يُستخدم كومبيجان لدى الأطفال الأصغر سناً من عامين وينبغي ألا يُستعمل بشكل اعتيادي لدى</p><p dir="RTL">&nbsp;&nbsp;الأطفال من سنتين إلى 17 سنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية</strong><strong> الأخرى</strong><strong> </strong><strong>و كومبيجان&nbsp;</strong></p><p dir="RTL"><strong>يمكن لـ كومبيجان التأثير على أو التأثر من أدوية أخرى تتعاطاها، بما في ذلك قطرات أخرى للعين تُستخدم لعلاج الغلوكوما</strong>. قم بابلاغ طبيبك أو الصيدلي إذا كنت تستعمل، أو استعملت مؤخراً، أي أدوية أخرى، بما فيها الأدوية المستخدمة لأي حالة طبية، حتى إذا لم تكن لها صلة بحالتك العينية، بما في ذلك الأدوية التي تُصرف بدون تذكرة طبية. هناك عدد من الأدوية التي قد تعيق كومبيجان، وبناء عليه، فمن المهم أن تخبر طبيبك إذا كنت تتعاطى:</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">مسكنات</li><li dir="RTL">أدوية تساعد على النوم أو على مواجهة القلق</li><li dir="RTL">أدوية لعلاج ارتفاع ضغط الدم</li><li dir="RTL">أدوية للحالات القلبية (على سبيل المثال، ضربات قلب غير طبيعية) كمُحصرات البيتا، ديجوكسين أو كينيدين (يستعملوا لعلاج حالات قلبية وبعض أنواع الملاريا [البُرداء])</li><li dir="RTL">أدوية لعلاج السكري أو ارتفاع سكر الدم</li><li dir="RTL">أدوية تعالج الاكتئاب مثل فلوكسيتين و باروكسيتين</li><li dir="RTL">قطرة أخرى للعين تُستعمل لتخفيض الضغط المرتفع داخل العين (الغلوكوما)</li><li dir="RTL">أدوية لعلاج التفاعلات الأرجية (التحسسية) الشديدة</li><li dir="RTL">أدوية تؤثر على بعض الهرمونات في جسمك، مثل الأدرينالين والدوبامين</li><li dir="RTL">أدوية تؤثر على العضلات الموجودة في أوعيتك الدموية</li><li dir="RTL">أدوية تعالج حُرقة المعدة أو قُرح المعدة</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تغيرت جرعة أي من أدويتك الحالية أو إذا كنت تشرب الكحوليات بانتظام، سيكون عليك إخبار طبيبك.</p><p dir="RTL">إذا كنت ستخضع للتخدير، ينبغي عليك إخبار طبيبك أو طبيب أسنانك بأنك تتلقى كومبيجان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong><strong> والإرضاع</strong></p><p dir="RTL">&nbsp;اذا كنت حاملا او ترضعين او تظنين ربما ان تكوني حاملا او تخططين للحمل , استشيري طبيبك او الصيدلي قبل استعمال هذا الدواء.لا تستعملي كومبيجان إذا كنت حاملاً &nbsp;ما لم يقرر طبيبك أنه ضروري.</p><p dir="RTL">لا تستعملي كومبيجان إذا كنتِ مرضعة. فقد يصل تيمولول إلى لبن الأم. أطلبي نُصحاً من طبيبك قبل أن تتعاطي أي دواء أثناء فترة الإرضاع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة</strong><strong> السيارة</strong><strong> وتشغيل</strong><strong> الآلات</strong></p><p dir="RTL">قد يسبب كومبيجان النعاس أو التعب أو غشاوة في الإبصار في بعض المرضى. امتنع عن قيادة السيارة أو تشغيل أية أدوات أو آلات إلى أن تزول هذه الأعراض. إذا حدثت لك أي مشاكل استشر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كومبيجان يحتوى بنزالكونيوم كلوريد &nbsp;</strong></p><p dir="RTL"><strong>هذا الدواء يحتوى </strong><strong>0.25 مجم بنزالكونيوم كلوريد فى كل 5 مل من المحلول والتى تعادل </strong><strong>0.05 &nbsp;مجم/مل</strong></p><ul><li dir="RTL">كلوريد البنزالكونيوم يمكن امتصاصه بواسطه العدسات اللاصقه اللينه وقد يؤدى ذلك الى تغير لون العدسات اللاصقة . يجب ازالة العدسات اللاصقه&nbsp; قبل استعمال هذا ألدواء و اعادة وضعها &nbsp;15 دقيقة بعد استعمال الدواء.</li><li dir="RTL">قد يسبب&nbsp; كلوريد البنزالكونيوم تهيج العين خاصة ان كنت تعانى من جفاف العين او لديك مشاكل فى القرنية(الطبقه الشفافه فى مقدمه العين) .&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><p>&nbsp;&nbsp;اذا شعرت بشعور غير طبيعى بالعين او حرقان او الم بالعين بعد استعمال الدواء اتصل بطبيبك مباشرة&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كومبيجان يحتوى على فوسفات </strong></p><p dir="RTL"><strong>هذا الدواء يحتوى على </strong><strong>52.9 </strong><strong>&nbsp;</strong><strong>مجم من الفوسفات فى كل 5 مل من المحلول والتى تعادل </strong><strong>10.58 </strong><strong>&nbsp;مجم </strong><strong>/</strong><strong> مل </strong></p><p dir="RTL">اذا كنت تعانى&nbsp; من تلف شديد فى الطبقة الشفافة الامامية للعين (القرنية), قد يسبب الفوسفات فى حالات نادره بقع غائمة على القرنية نتيجة تراكم &nbsp;الكالسيوم اثناء العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">التزم دائماً بتعليمات طبيبك عند استعمال هذا الدواء. استشر طبيبك أو الصيدلي إذا كنت غير متأكد من طريقة الاستعمال. يجب ألا يُستخدم كومبيجان لدى الأطفال الذين يقل عمرهم عن سنتان. وينبغي ألا يُستعمل بشكل اعتيادي لدى الأطفال والمراهقين (من سنتين إلى 17 سنة).</p><p dir="RTL">الجرعة المقرره هي نقطة واحدة من كومبيجان، مرتين يومياً بفارق حوالي 12 ساعة. لا تغير الجرعة ولا تتوقف عن استعمال الدواء بدون أن تتحدث مع طبيبك.</p><p dir="RTL">إذا كنت تستعمل قطرات أخرى للعين بجانب كومبيجان، <strong>يجب</strong><strong> أن</strong><strong> تمر</strong><strong> خمس</strong><strong> دقائق</strong><strong> على</strong><strong> الأقل</strong> بين استعمال كومبيجان والقطرات الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات</strong><strong> خاصة</strong><strong> بالاستعمال</strong></p><p dir="RTL">لا تستعمل الزجاجة إذا كانت سدادة الأمان على عنق الزجاجة مكسورة قبل أول استعمال.</p><p dir="RTL">اغسل يديك قبل فتح الزجاجة. أمل رأسك إلى الخلف وانظر إلى السقف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><img alt="" width="620" height="173" src="data:image/png;base64,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" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">١. اسحب الجفن السفلي برفق إلى أسفل بحيث يتكون جيب صغير.</p><p dir="RTL">٢. اقلب الزجاجة بحيث تتجه إلى أسفل، واضغط عليها بحيث تنزلق نقطة واحدة في كل عين تحتاج لعلاج.</p><p dir="RTL">٣. اترك الجفن السفلي، واغمض عينك.</p><p dir="RTL">٤. استمر في إغماض العين، واضغط بإصبعك على ركن العين (مكان التقاء العين بالأنف) لمدة دقيقتان. يساعد هذا على منع دخول كومبيجان إلى بقية الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تدخل النقطة في عينك، حاول مرة أخرى.</p><p dir="RTL">لتجنب التلوث، لا تدع طرف الزجاجة يلمس عينك أو أي شيء آخر. أعد الغطاء وأغلق الزجاجة فوراً بعد استعمالها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا</strong><strong> استعملت</strong><strong> كمية</strong><strong> أكبر</strong><strong> مما</strong><strong> ينبغي</strong><strong> من</strong><strong> كومبيجان</strong></p><p dir="RTL"><em>في</em><em> البالغين</em></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">إذا استعملت كمية أكبر مما ينبغي من كومبيجان، من المُستبعد أن يسبب ذلك أي أذى. استعمل الجرعة التالية في موعدها كالمعتاد. إذا شعرت بالقلق ناقش الأمر مع طبيبك أو الصيدلي.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>في الولدان والأطفال</em></p><p dir="RTL">تم الإبلاغ عن عدة حالات من تجاوز الجرعة في ولدان يتلقون بريمونيدين (أحد مكونات كومبيجان) كجزء من العلاج الطبي للغلوكوما. تشمل الأعراض: الميل للنعاس، الارتخاء، انخفاض درجة حرارة الجسم، الشحوب، صعوبات في التنفس. إذا حدثت هذا، يجب الاتصال فوراً بالطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>البالغون والأطفال</em></p><p dir="RTL">إذا بُلع كومبيجان عن طريق الخطأ فسيكون عليك الاتصال بطبيبك على الفور.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا</strong><strong> نسيت</strong><strong> أن</strong><strong> تستعمل</strong><strong> كومبيجان</strong></p><p dir="RTL">إذا نسيت أن تستعمل كومبيجان، استعمل نقطة واحدة في كل عين تحتاج إلى علاج بمجرد أن تتذكره، ثم ارجع إلى نظامك المعتاد. لا تستعمل جرعة مضاعفة للتعويض عن الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا</strong><strong> توقفت</strong><strong> عن</strong><strong> استعمال</strong><strong> كومبيجان</strong></p><p dir="RTL">يجب استعمال كومبيجان يومياً لكي يزاول مفعوله بشكل صحيح.</p><p dir="RTL">إذا كان لديك مزيد من الأسئلة عن استعمال هذا المنتج، الرجاء توجيهها إلى طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن جميع الأدوية، قد يؤدي هذا الدواء &nbsp;إلى آثار جانبية، وإن كانت لا تحدث لجميع الأشخاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تعرضت لأي من التأثيرات الجانبية التالية، رجاء الاتصال بطبيبك على الفور:</p><ul><li dir="RTL">فشل قلبي (على سبيل المثال، ألم الصدر) أو عدم انتظام ضربات القلب</li><li dir="RTL">ارتفاع أو انخفاض في معدل ضربات القلب أو انخفاض ضغط الدم</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>تصيب العين</u></em></p><p dir="RTL"><em>شائعة جداً(من الممكن ان تصيب اكثر من&nbsp; شخص &nbsp;من كل 10 اشخاص):</em></p><p dir="RTL">احمرار أو حُرقة العين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>شائعة:(ممكن ان تصيب شخصا من كل 10 اشخاص):</em></p><ul><li dir="RTL">لسعة أو ألم في العين</li><li dir="RTL">تفاعل حساسية في العين أو الجلد المحيط بها</li><li dir="RTL">تشققات صغيرة على سطح العين (مع التهاب أو بدونه)</li><li dir="RTL">تورم واحمرار والتهاب الجفون</li><li dir="RTL">التهيج، أو الإحساس بوجود شيء داخل العين</li><li dir="RTL">حكة بالعين والجفن</li><li dir="RTL">جريبات أو بقع بيضاء على الطبقة الشفافة التي تغطي سطح العين</li><li dir="RTL">اضطرابات بصرية</li><li dir="RTL">دُماع</li><li dir="RTL">جفاف العين</li><li dir="RTL">أعين دبقة</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>غير شائعة:(ممكن ان تصيب شخصا من كل 100 شخص)</em></p><ul><li dir="RTL">صعوبة في الرؤية بوضوح</li><li dir="RTL">تورم والتهاب الطبقة الشفافة التي تغطي سطح العين</li><li dir="RTL">عيون متعبة</li><li dir="RTL">حساسية للضوء</li><li dir="RTL">الم الجفن</li><li dir="RTL">تحول لون الطبقة الشفافة التي تغطي سطح العين إلى الأبيض</li><li dir="RTL">تورم أو مناطق من الالتهاب تحت سطح العين</li><li dir="RTL">عوائم أمام العين</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>غير معروفة:(لا يمكن تقديرها من المعلومات المتاحه):</em></p><ul><li dir="RTL">غشاوة البصر</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>تصيب الجسم</em></p><p dir="RTL"><em>شائعة:(من الممكن ان تصيب حتى شخصا من كل 10 اشخاص):</em></p><ul><li dir="RTL">ارتفاع ضغط الدم</li><li dir="RTL">الاكتئاب</li><li dir="RTL">النوام</li><li dir="RTL">الصداع</li><li dir="RTL">جفاف الفم</li><li dir="RTL">الضعف العام</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>غير شائعة:(ممكن ان تصيب حتى شخصا من كل 100 شخص):</em></p><ul><li dir="RTL">الفشل القلبي</li><li dir="RTL">عدم انتظام ضربات القلب</li><li dir="RTL">الدوخة</li><li dir="RTL">الإغماء</li><li dir="RTL">جفاف الأنف</li><li dir="RTL">اضطرابات حاسة التذوق</li><li dir="RTL">الغثيان</li><li dir="RTL">الإسهال</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>غير معروفة:(لا يمكن تقديرها من المعلومات المتاحه):</em></p><ul><li dir="RTL">ارتفاع معدل ضربات القلب أو انخفاضه</li><li dir="RTL">انخفاض ضغط الدم</li><li dir="RTL">تورد الوجه</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">قد تكون بعض هذه التأثيرات ناجمة عن تحسس (حساسية) تجاه أي من المكونات. شوهدت تأثيرات جانبية إضافية مع بريمونيدين أو تيمولول، وبالتالي، فمن الممكن حدوثها مع كومبيجان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">شوهدت التأثيرات الجانبية الإضافية التالية مع بريمونيدين:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب داخل العين، حدقات صغيرة، صعوبة في النوم، أعراض شبيهة بنزلة البرد، ضيق التنفس، أعراض خاصة بالمعدة والهضم، تفاعلات أرجية (تحسسية) عامة، تفاعلات جلدية تضم التورد، تورم الوجه، طفح حاك وتوسع الأوعية الدموية.</p><p dir="RTL">مثله مثل الأدوية الأخرى المُستخدمة على العين، يُمتص كومبيجان (بريمونيدين/تيمولول) وصولاً إلى الدم. تيمولول هو المكون المُحصر للبيتا الموجود في كومبيجان وامتصاصه قد يُسبب تأثيرات جانبية مطابقة لتلك التي تنجم عن استعمال عوامل إحصار البيتا الفموية و/أو الوريدية. إلا أن معدل وقوع التأثيرات الجانبية أكثر انخفاضا بعد الاستعمال الظاهري على العين مقارنة باستعمال الأدوية عن طريق الفم أو الحَقن، على سبيل المثال. تضم التأثيرات الجانبية المُدرجة تفاعلات شوهدت داخل فئة مُحصرات البيتا عندما تُستخدم لعلاج حالات العين:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفاعلات الأرجية (التحسسية) المُتعممة، بما فيها التورم تحت الجلدي (التي تصيب مناطق مثل الوجه والأطراف، والتي قد تسد المسلك الهوائي مما قد يُسبب صعوبة في البلع أو التنفس)، الشرى (أو الطفح الحاك)، الطفح الموضعي أو المُتعمم، الحكة وتفاعل جلدي مفاجئ وشديد يتهدد الحياة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات سكر الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم (أرق)، كوابيس، فقدان للذاكرة و الهلوسة .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكتة الدماغية، انخفاض الإمداد الدموية إلى المخ، زيادة علامات وأعراض الوهن العضلي الوبيل (اضطراب عضلي)، إحساس غير معتاد (كوخز الإبر).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القرنية، انفصال الطبقة الموجودة تحت الشبكية التي تحتوي على أوعية دموية بعد جراحة الترشيح مما قد يُسبب اضطرابات بصرية، انخفاض حساسية القرنية، تآكل القرنية (تضرر الطبقة الأمامية لمقلة العين)، تدلي الجفن العلوي (مما يجعل العين نصف مغلقة)، الرؤية المزدوجة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر، الوذمة (تراكم السوائل)، تغيرات في نظم أو سرعة ضربات القلب، نوع من اضطرابات نظم القلب، النوبة القلبية والفشل القلبي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظاهرة رينود، برودة اليدان والقدمان.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضيق المسالك الهوائية بالرئتين (بالذات لدى المرضى الموجودة لديهم هذه الحالة أصلاً)، صعوبة في التنفس والسعال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عُسر الهضم، ألم البطن والقيء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر، طفح جلدي يبدو لونه أبيض فضيّ (طفح صدفيّ الشكل) أو تدهور الصدفية، والطفح الجلدي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم عضلي غير ناجم عن مجهود بدني.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل وظيفي جنسي، انخفاض الشهوة الجنسية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات أو إصابتها بالإرهاق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اعراض جانبية اخرى رصدت مع استعمل قطرات العيون المحتويه على الفوسفات:</p><p dir="RTL">تم الإبلاغ عن حالات تكلس القرنية في حالات نادرة جدًا مع استخدام قطرات العين التى تحتوى&nbsp; فوسفات فى &nbsp;بعض المرضى الذين يعانون من تلف شديد في القرنية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الابلاغ غن الاثار الجانبيه</strong></p><p dir="RTL">إذا حصل لك أي من التأثيرات الجانبية، &nbsp;هذا يشمل أي تأثير جانبي غير مذكور في هذه النشرة، برجاء إبلاغ طبيبك أو الصيدلي. يمكنك ايضا الابلاغ عن الاثار الجانبية&nbsp; مباشرة عن طريق نظام الابلاغ الوطني المذكور في القسم 6. &nbsp;</p><p dir="RTL">بالابلاغ عن الاعراض الجانبيه انت تساعد فى اعطاء معلومات اكثر عن سلامه هذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيداً عن متناول ومرأى الأطفال.</p><p>يحفظ فى درجة حرارة لا تتجاوز 25 درجة مئوية.</p><p>لا يحفظ في الثلاجة ولا يجمد.</p><p dir="RTL">احفظ الزجاجة في العلبة الخارجية لحمايتها من الضوء.</p><p dir="RTL">يجب أن تتخلص من الزجاجة بعد اربعة أسابيع من فتحها.</p><p dir="RTL">لا تستعمل أكثر من زجاجة في وقت واحد.</p><p dir="RTL">لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على مُلصق الزجاجة وعلى العلبة الخارجية أمام العلامة &quot;EXP.&quot;. تاريخ انتهاء الصلاحية يُشير إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">يجب أن تتخلص من الزجاجة بعد أربعة أسابيع من فتحها، حتى إذا تبقى بداخلها بعض النقط، وذلك لتجنب العدوى. لمساعدتك على تذكر ذلك، اكتب تاريخ فتح الزجاجة في المسافة الخالية على العلبة.</p><p dir="RTL">لا ينبغي التخلص من الأدوية بإلقائها في مياه الصرف.او مع القمامه المنزليه. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم يعد لها استعمال. هذه الإجراءات تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات كومبيجان</strong></p><ul><li dir="RTL">المواد الفعالة هي بريمونيدين تارترات وتيمولول.</li><li dir="RTL">يحتوي الملليلتر الواحد من المحلول على 2 ملليجرام بريمونيدين تارترات وتيمولول ماليات بما يكافئ 5 ملليجرام تيمولول.</li><li dir="RTL">المكونات الأخرى هي كلوريد بنزالكونيوم (مادة حافظة)، فوسفات صوديوم أحادي القاعدة أحادي التميؤ، فوسفات صوديوم ثنائي القاعدة سباعي التميؤ، وماء منقى. يمكن إضافة كميات صغيرة من حمض الهيدروكلوريك أو هيدروكسيد الصوديوم لتصحيح الأس الهيدروجيني للمحلول (درجة الحموضة أو القلوية للمحلول).</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كومبيجان هو قطرة للعين في شكل محلول رائق، لونه أصفر مائل إلى الأخضر، في زجاجة بلاستيكية ذات غطاء لولبي. كل زجاجة ممتلئة إلى نصفها تقريباً، وتحتوي على 5 ملليلتر من المحلول. العبوات المتوفرة بها زجاجة واحدة أو ثلاث زجاجات. قد لا تكون كل أحجام العبوات متاحة في كل الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>ألليرجان فارماسيوتيكالس أيرلندا، كاسلبار رود، وستبورت، كو مايو، أيرلندا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            روجعت هذه النشرة آخر مرة في ديسمبر 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Combigan 2mg/ml + 5mg/ml eye drops, solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ml solution contains:
2.0 mg brimonidine tartrate, equivalent to 1.3 mg of brimonidine
5.0 mg timolol as 6.8 mg timolol maleate
Excipient(s) with known effect

Contains benzalkonium chloride 0.05 mg/mL.
Contains phosphates 10.58 mg/mL.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye drops, solution.

Clear, greenish yellow solution

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reduction of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><p>Recommended dosage in adults (including the elderly)</p><p>The recommended dose is one drop of Combigan in the affected eye(s) twice daily, approximately 12 hours apart</p><p><u>&nbsp;</u></p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>Combigan is contraindicated in neonates and infants aged less than 2 years (see section 4.3 Contraindications, section 4.4 Special warnings and precautions for use, section 4.8 Undesirable effects and section 4.9 Overdose).</p><p>&nbsp;</p><p>The safety and efficacy of Combigan in children and adolescents aged &nbsp;2 to 17 years have not been established and therefore, its use is not recommended in children or adolescents (see also section 4.4 and section 4.8 and section 4.9).</p><p>&nbsp;</p><p><em>Use in renal and hepatic impairment</em></p><p>Combigan has not been studied in patients with hepatic or renal impairment. Therefore, caution should be used in treating such patients.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>As with any eye drops, to reduce possible systemic absorption, it is recommended that the lachrymal sac be compressed at the medial canthus (punctual occlusion) or eyelids are closed for two minutes. This should be performed immediately following the instillation of each drop.&nbsp; This may result in a decrease of systemic side effects and an increase in local activity.</p><p>&nbsp;</p><p>To avoid contamination of the eye or eye drops do not allow the dropper tip to come into contact with any surface</p><p>&nbsp;</p><p>If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ••	Hypersensitivity to the active substances or any of the excipients listed in section 6.
•	Reactive airway disease including bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease.
•	Sinus bradycardia, sick sinus syndrome sino-atrial block, second or third degree atrioventricular block not controlled with a pace-maker, overt cardiac failure, cardiogenic shock.
•	Use in neonates and infants (less than 2 years of age) (see section 4.8)
•	Patients receiving monoamine oxidase (MAO) inhibitor therapy.
•	Patients on  antidepressants which affect noradrenergic transmission (e.g. tricyclic antidepressants and mianserin)



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Paediatric population</u></p><p>Children of 2 years of age and above, especially those in the 2-7 age range and/or weighing &le;20 Kg, should be treated with caution and closely monitored due to the high incidence and severity of somnolence. The safety and effectiveness of Combigan in children and adolescents (2 to 17 years of age) have not been established (see section 4.2 and section 4.8).</p><p>&nbsp;</p><p><em>Eye disorders</em></p><p>Some patients have experienced ocular allergic type reactions (allergic conjunctivitis and allergic blepharitis) with Combigan in clinical trials. Allergic conjunctivitis was seen in 5.2% of patients. Onset was typically between 3 and 9 months resulting in an overall discontinuation rate of 3.1%. Allergic blepharitis was uncommonly reported (&lt;1%). If allergic reactions are observed, treatment with Combigan should be discontinued.</p><p>&nbsp;</p><p>Delayed ocular hypersensitivity reactions have been reported with brimonidine tartrate ophthalmic solution 0.2%, with some reported to be associated with an increase in IOP.</p><p>&nbsp;</p><p>Combigan has not been studied in patients with closed-angle glaucoma.</p><p><em>Systemic effects</em></p><p>&nbsp;</p><p>Like other topically applied ophthalmic agents, Combigan may be absorbed systemically. No enhancement of the systemic absorption of the individual active substances has been observed. Due to the beta-adrenergic component, timolol, the same types of cardiovascular, pulmonary and other adverse reactions seen with systemic beta-adrenergic blocking agents may occur. &nbsp;Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. To reduce the systemic absorption, see section 4.2.</p><p>&nbsp;</p><p><em>Cardiac disorders:</em></p><p><em>&nbsp;</em>Cardiac reactions have been reported including, rarely, death associated with cardiac</p><p>failure following administration of timolol.In patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal&#39;s angina and cardiac failure) and hypotension therapy with beta-blockers should be critically assessed and the therapy with other active substances should be considered. Patients with cardiovascular diseases should be watched for signs of deterioration of these diseases and of adverse reactions.</p><p>&nbsp;</p><p>Due to its negative effect on conduction time, beta-blockers should only be given with caution to patients with first degree heart block.</p><p>&nbsp;</p><p>As with systemic beta-blockers, if discontinuation of treatment is needed in patients with coronary heart disease, therapy should be withdrawn gradually to avoid rhythm disorders, myocardial infarction or sudden death</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Vascular disorders</em></p><p>Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud&rsquo;s disease or Raynaud&rsquo;s syndrome) should be treated with caution.</p><p>&nbsp;</p><p><em>Respiratory disorders</em></p><p>Respiratory reactions, including death due to bronchospasm in patients with asthma have been reported following administration of some ophthalmic beta-blockers.</p><p>Combigan<em>&nbsp; </em>should be used with caution, in patients with mild/moderate chronic</p><p>obstructive pulmonary disease (COPD) and only if the potential benefit outweighs the potential risk.</p><p>&nbsp;</p><p><em>Hypoglycaemia/diabetes </em></p><p>Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to patients with labile diabetes, as beta-blockers may mask the signs and symptoms of acute hypoglycaemia.</p><p>&nbsp;</p><p><em>Hyperthyroidism </em></p><p>Beta-blockers may also mask the signs of hyperthyroidism.</p><p>&nbsp;</p><p>Combigan must be used with caution in patients with metabolic acidosis and untreated phaeochromocytoma.</p><p>&nbsp;</p><p><em>Corneal diseases </em></p><p>Ophthalmic beta-blockers may induce dryness of eyes. Patients with corneal diseases should be treated with caution.</p><p>&nbsp;</p><p><em>Other beta-blocking agents </em></p><p>The effect on intra-ocular pressure or the known effects of systemic beta-blockade may be potentiated when timolol is given to the patients already receiving a systemic beta-blocking agent. The response of these patients should be closely observed. The use of two topical beta-adrenergic blocking agents is not recommended (see section 4.5).</p><p>&nbsp;</p><p><em>Anaphylactic reactions </em></p><p>While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens and unresponsive to the usual dose of adrenaline used to treat anaphylactic reactions.</p><p>&nbsp;</p><p><em>Choroidal detachment</em></p><p>Choroidal detachment has been reported with administration of aqueous suppressant therapy (e.g. timolol, acetazolamide) after filtration procedures.</p><p>&nbsp;</p><p><em>Surgical anaesthesia</em></p><p>Beta-blocking ophthalmological preparations may block systemic beta-agonist effects e.g. of adrenaline. The anaesthetist must be informed if the patient is receiving timolol.</p><p>&nbsp;</p><p><em>Benzalkonium chloride</em></p><p>The preservative in Combigan, benzalkonium chloride, may cause eye irritation. symptoms of dry eyes, and may affect the tear film and corneal surface with prolonged use. Remove contact lenses prior to application and wait at least 15 minutes before reinsertion. Benzalkonium chloride is known to discolour soft contact lenses. Avoid contact with soft contact lenses.</p><p>&nbsp;</p><p>Combigan should be used with caution in dry eye patients and in patients where the cornea may be compromised. Patients should be monitored in case of prolonged use.</p><p>&nbsp;</p><p><em>Phosphates buffer</em></p><p>Combigan contains phosphates, which may cause in very rare cases cloudy patches on the cornea due to calcium build-up during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed with the brimonidine timolol fixed combination. Although specific drug interactions studies have not been conducted with Combigan, the theoretical possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anaesthetics) should be considered.</p><p>&nbsp;</p><p>There is potential for additive effects resulting in hypotension, and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with oral calcium channel blockers, beta-adrenergic blocking agents, antiarrhythmics (including amiodarone), digitalis glycosides, parasympathomimetics or guanethidine</p><p>.</p><p>Also, after the application of brimonidine, very rare (&lt;1 in 10,000) cases of hypotension have been reported. Caution is therefore advised when using Combigan with systemic antihypertensives.</p><p>&nbsp;</p><p>Mydriasis resulting from concomitant use of ophthalmic beta-blockers and adrenaline (epinephrine) has been reported occasionally. Beta-blockers may increase the hypoglycaemic effect of antidiabetic agents. Beta-blockers can mask the signs and symptoms of hypoglycaemia (see 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p>The hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta-blockers.</p><p>&nbsp;</p><p>Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine) and timolol.&nbsp;</p><p>&nbsp;</p><p>Concomitant use of a beta-blocker with anaesthetic drugs may attenuate compensatory tachycardia and increase the risk of hypotension (see section 4.4), and therefore the anaesthetist must be informed if the patient is using Combigan.</p><p>&nbsp;</p><p>Caution must be exercised if Combigan is used concomitantly with iodine contrast products or intravenously administered lidocain.</p><p>&nbsp;</p><p>Cimetidine, hydralazine and alcohol may increase the plasma concentrations of timolol.</p><p>&nbsp;</p><p>No data on the level of circulating catecholamines after Combigan administration are available. Caution, however, is advised in patients taking medication which can affect the metabolism and uptake of circulating amines e.g. chlorpromazine, methylphenidate, reserpine.</p><p>&nbsp;</p><p>Caution is advised when initiating (or changing the dose of) a concomitant systemic agent (irrespective of pharmaceutical form) which may interact with a-adrenergic agonists or interfere with their activity i.e. agonists or antagonists of the adrenergic receptor e.g. (isoprenaline, prazosin).</p><p>&nbsp;</p><p>Although specific drug interactions studies have not been conducted with Combigan, the theoretical possibility of an additive IOP lowering effect with prostamides, prostaglandins, carbonic anhydrase inhibitors and pilocarpine should be considered.</p><p>&nbsp;</p><p>Brimonidine is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy and patients on antidepressants which affect noradrenagic transmission (e.g. tricyclic antidepressants and miaserin), (see section 4.3). Patients who have been receiving MAOInhibitor therapy should wait 14 days after discontinuation before commencing treatment with Combigan.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pregnancy</u></em></p><p>There are no adequate data for the use of the brimonidine timolol fixed combination in pregnant women.&nbsp; Combigan should not be used during pregnancy unless clearly necessary. To reduce the systemic absorption, see section 4.2.</p><p>&nbsp;</p><p><em>Brimonidine tartrate</em></p><p>There are no adequate data from the use of brimonidine tartrate in pregnant women. Studies in animals have shown reproductive toxicity at high maternotoxic doses (see section 5.3 Preclinical safety data).&nbsp; The potential risk for humans is unknown.</p><p>&nbsp;</p><p><em>Timolol</em></p><p>Studies in animals have shown reproductive toxicity at doses significantly higher than would be used in clinical practice (see 5.3).</p><p><em>&nbsp;</em></p><p>Epidemiological studies have not revealed malformative effects but shown a risk for intra uterine growth retardation when beta-blockers are administered by the oral route. In addition, signs and symptoms of beta-blockade (e.g. bradycardia, hypotension, respiratory distress and hypoglycaemia) have been observed in the neonate when beta-blockers have been administered until delivery. If Combigan is administered in pregnancy up to the time of delivery, the neonate should be carefully monitored during the first days of life.</p><p><em>&nbsp;</em></p><p><u>Breast-feeding</u><em> </em></p><p><em>Brimonidine tartrate</em></p><p><em>&nbsp;</em></p><p>It is not known if brimonidine is excreted in human milk but it is excreted in the milk of the lactating rat.</p><p>&nbsp;</p><p><em>Timolol </em></p><p>&nbsp;</p><p>Beta-blockers are excreted in breast milk. However, at therapeutic doses of timolol in eye drops it is not likely that sufficient amounts would be present in breast milk to produce clinical symptoms of beta-blockade in the infant. To reduce the systemic absorption, see section 4.2</p><p>&nbsp;</p><p>Combigan should not be used by women breast-feeding infants.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Combigan has minor influence on the ability to drive and use machines. Combigan may cause transient blurring of vision, visual disturbance, fatigue and/or drowsiness which may impair the ability to drive or operate machines. The patient should wait until these symptoms have cleared before driving or using machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on 12 month clinical data, the most commonly reported ADRs &nbsp;were conjunctival hyperaemia (approximately 15% of patients) and burning sensation in the eye (approximately 11% of patients).&nbsp; The majority of these cases was mild and led to discontinuation rates of only 3.4% and 0.5% respectively.</p><p>&nbsp;</p><p>The following adverse drug reactions were reported during clinical trials with Combigan:</p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. The following terminologies have been used in order to classify the occurrence of undesirable effects: Very Common (&ge;1/10);</p><p>Common (&ge;1/100 to &lt;1/10);</p><p>Uncommon (&ge;1/1,000 to &lt;1/100);</p><p>Rare (&ge;1/10,000 to &lt;1/1,000);</p><p>Very rare (&lt;1/10,000),</p><p>Not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Eye disorders </em></p><p><em>&nbsp;</em></p><p>Very Common conjunctival hyperaemia, burning sensation</p><p>Common: stinging sensation in the eye, allergic conjunctivitis, corneal erosion, superficial punctuate keratitis, eye pruritus, conjunctival folliculosis, visual disturbance, blepharitis, epiphora, eye dryness, eye discharge, eye</p><p>pain, eye irritation, foreign body sensation</p><p>Uncommon: visual acuity worsened, conjunctival oedema, follicular conjunctivitis, allergic blepharitis, conjunctivitis, vitreous floater, asthenopia, photophobia, papillary hypertrophy, eyelid pain, conjunctival</p><p>blanching, corneal oedema, corneal infiltrates, vitreous detachment</p><p>&nbsp;</p><p><em>Psychiatric disorders</em></p><p><em>&nbsp;</em></p><p>Common: depression</p><p><em>&nbsp;</em></p><p><em>Nervous system disorders</em></p><p><em>&nbsp;</em></p><p>Common: somnolence, headache</p><p>Uncommon: dizziness, syncope</p><p><em>&nbsp;</em></p><p><em>Cardiac disorders</em></p><p><em>&nbsp;</em></p><p>Uncommon: congestive heart failure, palpitations</p><p><em>&nbsp;</em></p><p><em>Vascular disorders</em></p><p><em>&nbsp;</em></p><p>Common: hypertension</p><p><em>&nbsp;</em></p><p><em>Respiratory, thoracic and mediastinal disorders</em></p><p>Uncommon: rhinitis, nasal dryness</p><p><em>&nbsp;</em></p><p><em>Gastrointestinal disorders</em></p><p><em>&nbsp;</em></p><p>Common: oral dryness</p><p>Uncommon: taste perversion, nausea, diarrhoea</p><p><em>&nbsp;</em></p><p><em>Skin and subcutaneous tissue disorders</em></p><p><em>&nbsp;</em></p><p>Common: eyelid oedema, eyelid pruritus, eyelid erythema</p><p>Uncommon: allergic contact dermatitis</p><p><em>&nbsp;</em></p><p><em>General disorders and administration site conditions</em></p><p><em>&nbsp;</em></p><p>Common: asthenic conditions</p><p>&nbsp;</p><p>The following adverse drug reactions have been reported since Combigan has been marketed:</p><p><em>&nbsp;</em></p><p><em>Eye disorders:</em></p><p><em>&nbsp;</em></p><p>Not known: vision blurred</p><p><em>&nbsp;</em></p><p><em>Cardiac disorders</em></p><p><em>&nbsp;</em></p><p>Not known: arrhythmia, bradycardia, tachycardia</p><p><em>&nbsp;</em></p><p><em>Vascular disorders </em></p><p>&nbsp;</p><p>Not known: hypotension</p><p><em>&nbsp;</em></p><p><em>Skin disorders: </em>&nbsp;</p><p>&nbsp;</p><p>Not known: erythema facial</p><p>&nbsp;</p><p>Additional adverse events that have been seen with one of the components and may potentially occur also with Combigan:</p><p>&nbsp;</p><p><em>Brimonidine</em></p><p><em>&nbsp;</em></p><p><em>Eye disorders: </em>iritis, iridocyclitis (anterior uveitis), miosis</p><p>&nbsp;</p><p><em>Psychiatric disorders: </em>insomnia</p><p>&nbsp;</p><p><em>Respiratory, thoracic and mediastinal disorders: </em>upper respiratory symptoms, dyspnoea</p><p>&nbsp;</p><p><em>Gastrointestinal disorders: </em>gastrointestinal symptoms</p><p>&nbsp;</p><p><em>General disorders and administration site conditions: </em>systemic allergic reactions</p><p>&nbsp;</p><p><em>Skin and subcutaneous tissue disorders: </em>- skin reaction including erythema, face oedema, pruritus, rash and vasodilatation</p><p>&nbsp;</p><p>In cases where brimonidine has been used as part of the medical treatment of congenital glaucoma, symptoms of brimonidine overdose such as loss of consciousness, lethargy, somnolence, hypotension, hypotonia, bradycardia, hypothermia, cyanosis, pallor, respiratory depression and apnoea have been reported in neonates and infants (less than 2 years of age) receiving brimonidine (see section 4.3).</p><p>&nbsp;</p><p>A high incidence and severity of somnolence has been reported in children of 2 years of age and above, especially those in the 2-7 age range and/or weighing &le;20 Kg (see section 4.4).</p><p>&nbsp;</p><p><em>Timolol </em></p><p>&nbsp;</p><p>Like other topically applied ophthalmic drugs, Combigan (brimonidine tartrate/ timolol) is absorbed into the systemic circulation. Absorption of timolol may cause similar undesirable effects as seen with systemic beta-blocking agents.</p><p>&nbsp;</p><p>Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. To reduce the systemic absorption, see section 4.2.</p><p>&nbsp;</p><p>Additional adverse reactions that have been seen with ophthalmic beta-blockers and may potentially occur also with Combigan are listed below:</p><p>&nbsp;</p><p><em>Immune system disorders: </em>systemic allergic reactions including angioedema, urticaria, localised and generalised rash, pruritis, anaphylactic reaction</p><p><em>&nbsp;</em></p><p><em>Metabolism: </em>hypoglycaemia</p><p><em>&nbsp;</em></p><p><em>Psychiatric disorders: </em>insomnia, nightmares, memory loss ,hallucination</p><p><em>&nbsp;</em></p><p><em>Nervous system disorders: </em>cerebrovascular accident, cerebral ischemia, increases in signs and symptoms of myasthenia gravis, paraesthesia</p><p><em>&nbsp;</em></p><p><em>Eye disorders</em>: keratitis<em>, choroidal</em> detachment following filtration surgery (see section 4.4 Special warnings and precautions for use), decreased corneal sensitivity, corneal erosion, ptosis, diplopia,</p><p>&nbsp;</p><p><em>Cardiac disorders: </em>chest pain, oedema, atrioventricular block,<em> </em>cardiac arrest, cardiac failure</p><p><em>&nbsp;</em></p><p><em>Vascular disorders: </em>Raynaud&#39;s phenomenon, cold hands and feet</p><p><em>&nbsp;</em></p><p><em>Respiratory, thoracic and mediastinal disorders: </em>bronchospasm (predominantly in patients with pre-existing bronchospastic disease) dyspnoea, cough</p><p><em>&nbsp;</em></p><p><em>Gastrointestinal disorders: </em>dyspepsia, abdominal pain, vomiting</p><p><em>&nbsp;</em></p><p><em>Skin and subcutaneous tissue disorders: </em>alopecia, psoriasiform rash or exacerbation of psoriasis, skin rash</p><p><em>&nbsp;</em></p><p><em>Musculoskeletal and connective tissue disorders: </em>myalgia</p><p><em>&nbsp;</em></p><p><em>Reproductive system and breast disorders: </em>sexual dysfunction, decreased libido</p><p><em>&nbsp;</em></p><p><em>General disorders and administration site conditions: </em>fatigue</p><p>&nbsp;</p><p>Adverse reactions reported in eye drops containing phosphates:</p><p>Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&bull;&nbsp;&nbsp;&nbsp;Saudi Arabia:</p><p>-&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>- SFDA Call Center: 19999</p><p>- E-mail: npc.drug@sfda.gov.sa&nbsp; &nbsp;</p><p>- Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p>&Yuml;&nbsp; Other GCC States:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rare reports of overdosage with Combigan in humans resulted in no adverse outcome. Treatment of an overdose includes supportive and symptomatic therapy; a patient&rsquo;s airway should be maintained.</p><p>&nbsp;</p><p><em>Brimonidine</em></p><p><em>&nbsp;</em></p><p><em>Ophthalmic overdose (Adults): </em></p><p>In those cases received, the events reported have generally been those already listed as adverse reactions.</p><p>&nbsp;</p><p><em>Systemic overdose resulting from accidental ingestion (Adults):</em></p><p>There is very limited information regarding accidental ingestion of brimonidine in adults. The only adverse event reported to date was hypotension. It was reported that the hypotensive episode was followed by rebound hypertension. Oral overdoses of other alpha-2-agonists have been reported to cause symptoms such as hypotension, asthenia, vomiting, lethargy, sedation, bradycardia, arrhythmias, miosis, apnoea, hypotonia, hypothermia, respiratory depression and seizure.</p><p>&nbsp;</p><p><em>Paediatric population </em></p><p>Reports of serious adverse effects following inadvertent ingestion of brimonidine ophthalmic solution &nbsp;&nbsp;&nbsp;by paediatric subjects have been published or reported to Allergan. The subjects experienced symptoms of CNS depression, typically temporary coma or low level of consciousness, lethargy, somnolence, hypotonia, bradycardia, hypothermia, pallor, respiratory depression and apnoea, and required admission to intensive care with intubation if indicated. All subjects were reported to have made a full recovery, usually within 6-24 hours.</p><p>&nbsp;</p><p><em>Timolol</em></p><p><em>&nbsp;</em></p><p>Symptoms of systemic timolol overdose include: bradycardia, hypotension, bronchospasm, headache, dizziness and cardiac arrest. A study of patients showed that&nbsp;timolol did not dialyse readily.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pharmacotherapeutic group: </em>Ophthalmological - antiglaucoma preparations and miotics - beta-blocking agents - timolol, combinations</p><p>&nbsp;</p><p>ATC<em> code</em>: S0lED51</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>Combigan consists of two active substances: brimonidine tartrate and timolol maleate. These two components decrease elevated intraocular pressure (lOP) by complementary mechanisms of action and the combined effect results in additional lOP reduction compared to either compound administered alone. Combigan has a rapid onset of action.</p><p>&nbsp;</p><p>Brimonidine tartrate is an alpha-2 adrenergic receptor agonist that is 1000-fold more selective for the alpha-2 adrenoceptor than the alpha-l adrenoreceptor. This selectivity results in no mydriasis and the absence of vasoconstriction in microvessels associated with human retinal xenografts.</p><p>&nbsp;</p><p>It is thought that brimonidine tartrate lowers lOP by enhancing uveosc1eral outflow and reducing aqueous humour. formation.</p><p>&nbsp;</p><p>Timolol is a beta<sub>1</sub> and beta<sub>2</sub> &nbsp;non-selective adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anaesthetic (membrane-stabilising) activity. Timolol lowers lOP by reducing aqueous humour formation. The precise mechanism of action is not clearly established, but inhibition of the increased cyclic AMP synthesis caused by endogenous beta-adrenergic stimulation is probable.</p><p>&nbsp;</p><p><u>Clinical effects</u></p><p><u>&nbsp;</u></p><p>In three controlled, double-masked clinical studies, Combigan (twice daily) produced a clinically meaningful additive decrease in mean diurnal lOP conwared with timolol (twice daily) and brimonidine (twice daily or three times a day) when administered as monotherapy.</p><p>&nbsp;</p><p>In a study in patients whose lOP was insufficiently controlled following a minimal 3-week run-in on any monotherapy, additional decreases in mean diurnal lOP of 4.5,3.3 and 3.5 mmHg were observed during 3 months of treatment for Combigan (twice daily), timolol (twice daily) and brimonidine (twice daily), respectively. In this study, at trough, a significant additional decrease in lOP could only be demonstrated on comparison with brimonidine but not with timolol, however a positive trend was seen with superiority at all other timepoints. In the pooled data of the other two</p><p>trials statistical superiority versus timolol was seen throughout.</p><p>&nbsp;</p><p>In addition, the IOP lowering effect of Combigan was consistently non-inferior to that achieved by adjunctive therapy of brimonidine and timolol (all twice daily).</p><p>&nbsp;</p><p>The IOP lowering effect of Combigan has been shown to be maintained in double-masked studies of up to 12 months.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Combigan</em></p><p><em>&nbsp;</em></p><p>Plasma brimonidine and timolol concentrations were determined in a crossover study comparing the monotherapy treatments to Combigan treatment in healthy subjects. There were no statistically significant differences in brimonidine or timolol AUC between Combigan and the respective monotherapy treatments.&nbsp; Mean plasma C<sub>max</sub> values for brimonidine and timolol following dosing with Combigan were 0.0327 and 0.406 ng/ml respectively,</p><p>&nbsp;</p><p><em>Brimonidine</em></p><p><em>&nbsp;</em></p><p>After ocular administration of 0.2% eye drops solution in humans, plasma brimonidine concentrations are low.&nbsp; Brimonidine is not extensively metabolised in the human eye and human plasma protein binding is approximately 29%. The mean apparent half-life in the systemic circulation was approximately 3 hours after topical dosing in man.</p><p>&nbsp;</p><p>Following oral administration to man, brimonidine is well absorbed and rapidly eliminated. The major part of the dose (around 74% of the dose) was excreted as metabolites in urine within five days; no unchanged drug was detected in</p><p>urine. In vitro studies, using animal and human liver, indicate that the metabolism is mediated largely by aldehyde oxidase and cytochrome P450. Hence, the systemic elimination seems to be primarily hepatic metabolism.</p><p>&nbsp;</p><p>Brimonidine binds extensively and reversibly to melanin in ocular tissues without any untoward effects. Accumulation does not occur in the absence of melanin.</p><p>&nbsp;</p><p>Brimonidine is not metabolised to a great extent in human eyes.</p><p>&nbsp;</p><p><em>Timolol</em></p><p><em>&nbsp;</em></p><p>After ocular administration of a 0.5% eye drops solution in humans undergoing cataract surgery, peak timolol concentration was 898 ng/ml in the aqueous humour at one hour post-dose. Part of the dose is absorbed systemically where it is extensively metabolised in the liver. The half-life of timolol in plasma is about 7 hours. Timolol is partially metabolised by the liver with timolol and its metabolites excreted by the kidney. Timolol is not extensively bound to plasma protein.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The ocular and systemic safety profile of the individual components is well established. Non-clinical data reveal no special hazard for humans based on conventional studies of the individual components in safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenicity studies. Additional ocular repeated dose toxicity studies on Combigan also showed no special hazard for humans.</p><p>&nbsp;</p><p><em>Brimonidine</em></p><p><em>&nbsp;</em></p><p>Brimonidine tartrate did not cause any teratogenic effects in animals, but caused abortion in rabbits and postnatal growth reduction in rats at systemic exposures approximately 37-times and 134-times those obtained during therapy in</p><p>humans, respectively.</p><p>&nbsp;</p><p><em>Timolol</em></p><p><em>&nbsp;</em></p><p>In animal studies, beta-blockers have been shown to produce reduced umbilical blood flow, reduced foetal growth, delayed ossification and increased foetal and postnatal death, but no teratogenicity. With timolol, embryotoxicity (resorption) in rabbit and foetotoxicity (delayed ossification) in rats have been seen at high maternal doses.</p><p>Teratogenicity studies in mice, rats and rabbits, at oral doses of timolol up to 4200 times of that in the human daily dose of Combigan, showed no evidence of foetal&nbsp;malformation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Benzalkonium chloride</p><p>Sodium phosphate, monobasic monohydrate</p><p>Sodium phosphate, dibasic heptahydrate</p><p>Hydrochloric acid or sodium hydroxide to adjust pH</p><p>Purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                21 months.
After first opening: Use within 28 days.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep the bottle in the outer carton, in order to protect from light.</p><p>Do not store above 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>White low density polyethylene bottles with polystyrene screw caps. Each bottle has a fill volume of 5 ml.</p><p>&nbsp;</p><p>The following pack sizes are available: cartons containing 1 or 3 bottles of 5 ml.&nbsp; Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Allergan Pharmaceuticals Ireland
Castlebar Road
Westport
Co. Mayo
Ireland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                  December 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>